Gindameran
Highest phase reached
Phase 1
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Oligonucleotide
- Drug name
- Gindameran
- gindameran component of bnt 111 ny eso 1 fusion protein expressing rna
- Gindameran component of bnt-111 ny-eso-1 fusion protein expressing rna
- gindameran component of bnt111
- Gindameran component of bnt111
- gindameran component of fixvac
- Gindameran component of fixvac
- bnt 111 component ny eso 1 fusion protein expressing rna
- BNT-111 COMPONENT NY-ESO-1 FUSION PROTEIN EXPRESSING RNA
- bnt111 component gindameran
- BNT111 COMPONENT GINDAMERAN
- fixvac component gindameran
- FixVac component Gindameran
- fixvac rna melanoma vaccine component expressing the ny eso 1 fusion protein t cell antigen
- FIXVAC RNA MELANOMA VACCINE COMPONENT EXPRESSING THE NY-ESO-1 FUSION PROTEIN T-CELL ANTIGEN
- gindameran
- Gindameran
- gindameran [INN]
- GINDAMERAN [USAN]
- Gindameran [WHO-DD]
- gindameran inn
- gindameran usan
- gindameran who dd
- MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING CODON-OPTIMISED NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA ANTIGEN-1 (NY-ESO-1 CANCER/TESTIS ANTIGEN 1, CTAG1A) EXPRESSED AS A FUSION PROTEIN COMPRISING A SECRETORY SIGNAL PEPTIDE, NY-ESO-1, P2P16 TETANUS TOXOID-DERIVED HELPER EPITOPES AND A MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I TRANSMEMBRANE AND CYTOPLASMIC DOMAIN (MITD), CONNECTED BY THREE GLYCINE/SERINE-RICH (GS) LINKER PEPTIDES, FLANKED BY 5' AND 3' UNTRANSLATED REGIONS AND A 3' POLY(A) TAIL.
- messenger rna mrna 5 capped encoding codon optimised new york esophageal squamous cell carcinoma antigen 1 ny eso 1 cancer testis antigen 1 ctag1a expressed as a fusion protein comprising a secretory signal peptide ny eso 1 p2p16 tetanus toxoid derived helper epitopes and a major histocompatibility complex mhc class i transmembrane and cytoplasmic domain mitd connected by three glycine serine rich gs linker peptides flanked by 5 and 3 untranslated regions and a 3 poly a tail
- rbl 001 3
- RBL-001.3
- rbl001 3
- RBL001.3
- RNA (RECOMBINANT (1,2-(M7GM-P-(P(R))-SP-P-G))-CAPPED HUMAN CANCER TESTIS ANTIGEN NY-ESO-1-SPECIFYING POLY(A)-TAILED MESSENGER RBL001.3), INNER SALT
- RNA (recombinant [1,2-[m7Gm-p-[P(R)]-sp-p-G]]-capped human cancer testis antigen NY-ESO-1-specifying poly(A)-tailed messenger RBL001.3), inner salt -
- rna recombinant 1 2 m7gm p p r sp p g capped human cancer testis antigen ny eso 1 specifying poly a tailed messenger rbl001 3 inner salt
- CAS registry numbers
- 2348560-89-2
- ChEMBL ID
- CHEMBL5314612
- FDA ingredient codes (UNII)
- WGT2OMP6LX
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Protein
- Sequence
- GGGCGAACUAGUAUUCUUCUGGUCCCCACAGACUCAGAGAGAACCCGCCACCAUGAGAGUGAUGGCCCCCAGAACCCUGAUCCUGCUGCUGUCUGGCGCCCUGGCCCUGACAGAGACAUGGGCCGGAAGCGGCGGCUCUGGAGGAGGCGGCUCCGGAGGCAUGCAGGCCGAGGGCAGAGGAACAGGCGGCAGCACAGGCGACGCAGAUGGACCAGGCGGCCCUGGAAUCCCUGAUGGCCCAGGCGGCAAUGCUGGGGGACCAGGAGAAGCUGGCGCCACAGGCGGGAGAGGACCUAGAGGAGCUGGAGCCGCUAGAGCUUCUGGACCUGGGGGAGGCGCCCCUAGAGGACCACAUGGAGGCGCUGCCAGCGGCCUGAAUGGCUGCUGCAGAUGCGGCGCCAGAGGCCCUGAGAGCCGGCUGCUGGAAUUCUACCUGGCCAUGCCCUUCGCCACCCCCAUGGAAGCCGAGCUGGCCAGAAGAUCCCUGGCUCAGGACGCUCCUCCUCUGCCUGUGCCCGGCGUGCUGCUGAAAGAAUUCACCGUGUCCGGCAACAUCCUGACCAUCAGACUGACAGCCGCCGAUCACAGACAGCUCCAGCUGAGCAUCAGCUCUUGCCUGCAGCAGCUGAGCCUGCUGAUGUGGAUCACCCAGUGCUUUCUGCCCGUGUUCCUGGCCCAGCCACCCAGCGGACAGAGAAGGGGAGGAUCCGGUGGUGGCGGCAGCGGCGGCAAGAAGCAGUACAUCAAGGCCAACAGCAAGUUCAUCGGCAUCACCGAGCUGAAGAAGCUGGGAGGGGGCAAACGGGGAGGCGGCAAAAAGAUGACCAACAGCGUGGACGACGCCCUGAUCAACAGCACCAAGAUCUACAGCUACUUCCCCAGCGUGAUCAGCAAAGUGAACCAGGGCGCUCAGGGCAAGAAACUGGGCUCUAGCGGAGGGGGAGGCUCUCCUGGCGGGGGAUCUAGCAUCGUGGGAAUUGUGGCAGGACUGGCAGUGCUGGCCGUGGUGGUGAUCGGAGCCGUGGUGGCUACCGUGAUGUGCAGACGGAAGUCCAGCGGAGGCAAGGGCGGCAGCUACAGCCAGGCCGCCAGCUCUGAUAGCGCCCAGGGCAGCGACGUGUCACUGACAGCCUAGUAACUCGAGCUGGUACUGCAUGCACGCAAUGCUAGCUGCCCCUUUCCCGUCCUGGGUACCCCGAGUCUCCCCCGACCUCGGGUCCCAGGUAUGCUCCCACCUCCACCUGCCCCACUCACCACCUCUGCUAGUUCCAGACACCUCCCAAGCACGCAGCAAUGCAGCUCAAAACGCUUAGCCUAGCCACACCCCCACGGGAAACAGCAGUGAUUAACCUUUAGCAAUAAACGAAAGUUUAACUAAGCUAUACUAACCCCAGGGUUGGUCAAUUUCGUGCCAGCCACACCGAGACCUGGUCCAGAGUCGCUAGCCGCGUCGCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAUAUGACUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Related records
Trials (7)
- A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
- A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
- Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
- Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
- Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
- Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
In development for (1)
- Neoplasm Phase 1